Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

09/10/2026, 4:08 PM • The Motley Fool

2 Dividend Stocks Built to Hold Up When Markets Don't

The article recommends two Dividend Kings—Johnson & Johnson and AbbVie—as defensive dividend stocks that can provide steady income during market volatility. Both companies have demonstrated consistent dividend growth and strong business fundamentals in their pharmaceutical and healthcare portfolios.

09/09/2026, 10:10 AM • The Motley Fool

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

09/08/2026, 2:30 PM • The Motley Fool

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

09/07/2026, 1:00 PM • GlobeNewswire

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue), which provides stable annuity-like income streams. With valuation metrics below five-year averages and continued AI opportunities, the stock may represent a buying opportunity for aggressive growth investors despite its historical volatility.

09/05/2026, 3:15 PM • The Motley Fool

Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider

The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.

09/04/2026, 8:30 PM • GlobeNewswire

Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.

09/04/2026, 10:54 AM • GlobeNewswire

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now

Bristol Myers Squibb and Pfizer are recommended as undervalued pharmaceutical stocks offering above-average dividend yields. BMY offers a safer 3.76% yield with a sustainable 45% FCF payout ratio and growing oncology portfolio, while PFE provides a higher 6.04% yield but with a riskier 89% payout ratio. Both trade at steep discounts to peers despite facing patent expiration challenges.

09/02/2026, 12:30 PM • The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.

09/02/2026, 12:12 PM • The Motley Fool

Vanguard Health Care ETF vs Simplify Health Care ETF

Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 1.5% dividend yield, while Simplify Health Care ETF (PINK) provides active management with higher 1-year returns (32.4% vs 29.3%) but charges 0.51% in fees. The author recommends Simplify despite Vanguard's better year-to-date performance, citing Simplify's superior longer-term returns and its pro bono model donating profits to breast cancer research.

09/01/2026, 3:12 PM • The Motley Fool

Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel

The global palmoplantar pustulosis market is experiencing steady growth driven by increased awareness, diagnosis rates, and development of targeted biologic therapies. Key advances in IL-23 and IL-36 research, precision medicine, and AI-assisted diagnostics are accelerating treatment development. While topical therapies remain central for mild cases, systemic agents and biologics are supporting moderate-to-severe disease management. Growth is reinforced by clinical trials and regulatory approvals across North America, Europe, and Asia-Pacific, though high treatment costs and limited access in developing regions remain challenges.

08/31/2026, 5:03 AM • GlobeNewswire

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

08/28/2026, 7:07 AM • The Motley Fool

I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

Johnson & Johnson stands out as an attractive dividend stock due to its diversified healthcare business, strong financial health with an AAA credit rating, impressive 64-year dividend increase streak, and recent progress in resolving talc-related lawsuits. Despite patent cliffs and drug price negotiations, the company expects 6.8% revenue growth for fiscal 2026, demonstrating resilience.

08/26/2026, 3:15 PM • The Motley Fool

Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

08/26/2026, 7:57 AM • GlobeNewswire